OPGN · Opgen Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $30.20M | $5.20M | $3.42M | $4.31M | $4.31M | $4.21M |
| Cost of Revenue | - | - | $3.08M | $2.30M | - | - |
| Gross Profit | - | - | $334.2K | $2.01M | - | - |
| R&D | $6.6K | $48.8K | $4.73M | $8.17M | $10.91M | $9.96M |
| SG&A | $3.13M | $4.54M | $8.08M | $8.88M | $9.94M | $8.80M |
| Total Operating Expenses | $6.17M | $4.87M | $34.17M | $37.17M | $27.58M | $26.93M |
| D&A | $191.5K | $174.8K | $1.32M | $1.64M | $2.71M | $2.33M |
| Operating Income | $24.03M | $324.7K | ($30.75M) | ($34.57M) | ($23.27M) | ($22.72M) |
| Interest Expense | $11.2K | $7.6K | $1.84M | $3.26M | $4.80M | $3.40M |
| Income Tax | $813.8K | $176.7K | - | - | $43.8K | $132.4K |
| Net Income | $23.62M | $11.99M | ($32.67M) | ($37.28M) | ($34.81M) | ($26.21M) |
| EPS - Basic | $2.33 | $2.44 | ($41.47) | ($22.89) | - | - |
| EPS - Diluted | $2.32 | $2.30 | ($41.47) | ($22.89) | - | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $531.3K | $1.31M | $1.15M | $7.44M | $36.08M | $13.36M |
| Accounts Receivable | $248.8K | $29.3K | $103.3K | $514.4K | $1.17M | $653.1K |
| Inventory | - | $1.23M | - | $3.65M | $4.71M | $1.49M |
| Accounts Payable | $1.08M | $245.2K | $111.1K | $420.8K | $1.31M | $1.87M |
| Current Assets | $988.2K | $2.65M | $1.58M | $10.66M | $39.74M | $16.89M |
| Total Assets | $38.06M | $9.86M | $1.88M | $25.81M | $71.67M | $49.75M |
| Current Liabilities | $4.55M | $634.2K | $11.42M | $10.59M | $19.92M | $7.37M |
| Long-term Debt | - | - | - | $4.85M | $7.18M | $19.38M |
| Total Liabilities | $6.20M | $2.48M | $13.44M | $18.24M | $30.45M | $28.56M |
| Stockholders' Equity | $31.86M | $7.38M | ($11.56M) | $7.58M | $41.22M | $21.19M |
| Retained Earnings | ($269.88M) | ($293.50M) | ($305.49M) | ($272.82M) | ($235.54M) | ($200.74M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($1.18M) | ($4.87M) | ($14.32M) | ($20.45M) | ($21.48M) | ($23.40M) |
| Investing Cash Flow | ($49.5K) | - | ($800.4K) | ($590.8K) | ($1.98M) | ($1.06M) |
| Financing Cash Flow | $496.7K | $5.03M | $8.37M | ($6.74M) | $47.45M | $34.09M |
| CapEx | $50.0K | - | $800.4K | $590.8K | $1.98M | $130.4K |
| Free Cash Flow | ($1.23M) | - | ($15.12M) | ($21.04M) | ($23.46M) | ($23.53M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | 9.8% | 46.7% | - | - |
| Operating margin | 79.6% | 6.2% | -899.5% | -802.8% | -540.5% | -539.1% |
| EBITDA margin | 80.2% | 9.6% | -861.0% | -764.6% | -477.4% | -483.7% |
| Net margin | 78.2% | 230.8% | -955.7% | -865.8% | -808.3% | -621.9% |
| Free cash flow margin | -4.1% | - | -442.3% | -488.6% | -544.9% | -558.2% |
| FCF / Net income | -0.05 | - | 0.46 | 0.56 | 0.67 | 0.90 |
| R&D / Revenue | 0.0% | 0.9% | 138.5% | 189.8% | 253.4% | 236.4% |
| SG&A / Revenue | 10.4% | 87.4% | 236.4% | 206.3% | 230.7% | 208.8% |
| Effective tax rate | 3.3% | 1.5% | - | - | - | - |
| Return on assets | 62.1% | 121.6% | -1735.6% | -144.4% | -48.6% | -52.7% |
| Return on equity | 74.1% | 162.5% | 282.6% | -492.2% | -84.4% | -123.7% |
| Return on invested capital | - | - | - | - | -38.0% | -44.2% |
| Liquidity | ||||||
| Current ratio | 0.22 | 4.18 | 0.14 | 1.01 | 2.00 | 2.29 |
| Quick ratio | 0.22 | 2.24 | 0.14 | 0.66 | 1.76 | 2.09 |
| Cash ratio | 0.12 | 2.07 | 0.10 | 0.70 | 1.81 | 1.81 |
| Leverage | ||||||
| Debt / Equity | - | - | - | 0.64 | 0.17 | 0.91 |
| Debt / Assets | - | - | - | 0.19 | 0.10 | 0.39 |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | 2136.8x | 43.0x | -16.7x | -10.6x | -4.8x | -6.7x |
| Equity multiplier | 1.19 | 1.34 | -0.16 | 3.41 | 1.74 | 2.35 |
| Liabilities / Assets | 0.16 | 0.25 | 7.14 | 0.71 | 0.42 | 0.57 |
| Efficiency | ||||||
| Asset turnover | 0.79 | 0.53 | 1.82 | 0.17 | 0.06 | 0.08 |
| Inventory turnover | - | - | - | 0.63 | - | - |
| Days sales outstanding | 3d | 2d | 11d | 44d | 99d | 57d |
| Days inventory outstanding | - | - | - | 580d | - | - |
| Days payable outstanding | - | - | 13d | 67d | - | - |
| Cash conversion cycle | - | - | - | 556d | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | 481.2% | 52.0% | -20.6% | 0.0% | 2.2% | 20.5% |
| Revenue CAGR (3y) | 91.4% | 6.5% | -6.7% | 7.2% | 10.3% | 9.5% |
| Revenue CAGR (5y) | 48.3% | 8.2% | 1.3% | 6.0% | 1.4% | 0.4% |
| Gross profit growth (YoY) | - | - | -83.4% | - | - | - |
| Operating income growth (YoY) | 7299.7% | - | 11.0% | -48.5% | -2.4% | -85.1% |
| Net income growth (YoY) | 97.0% | - | 12.4% | -7.1% | -32.8% | -110.6% |
| EPS growth (YoY) | 0.9% | - | -81.2% | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | 28.1% | 10.3% | 0.3% | -103.9% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | 331.6% | - | - | -81.6% | 94.5% | 393.6% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$30.20M totalListing Sponsorship Services$30.20M · 100.0%
Geographic
$30.20M totalInternational$30.20M · 100.0%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
-1.16
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
2/9
Weak
- ✓Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✗Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✗No share dilution
- -Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Services-Medical Laboratories
Comparing OPGEN INC against the 5 most active filers in the same SIC group.